Treatment for Vitamin D Level of 13 ng/mL
Treat with 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily 1.
Initial Treatment Phase
A vitamin D level of 13 ng/mL represents clear deficiency (below the 30 ng/mL target). The Endocrine Society guideline provides the definitive treatment approach:
- 50,000 IU weekly for 8 weeks (either vitamin D2 or D3)
- Alternative: 6,000 IU daily for 8 weeks if weekly dosing is not feasible
- Goal: Raise 25(OH)D above 30 ng/mL 1
This regimen is well-established and effective for correcting deficiency in most adults. Recent research confirms that weekly high-dose protocols (100,000 IU weekly for 12 weeks) can achieve and maintain therapeutic levels, though the standard 50,000 IU weekly remains the guideline-recommended approach 2.
Maintenance Phase
After the 8-week correction phase:
- 1,500-2,000 IU daily for ongoing maintenance 1
- This prevents recurrence of deficiency
- Alternative maintenance: 50,000 IU every 2 weeks has been shown effective in maintaining levels between 35-50 ng/mL 1
Special Considerations Requiring Dose Adjustment
Higher doses (2-3 times standard) are needed for:
- Obese patients: Require at least 6,000-10,000 IU daily for treatment, then 3,000-6,000 IU daily maintenance 1
- Malabsorption syndromes: Same higher dosing as obesity 1
- Medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids): Same higher dosing 1
Monitoring
- Recheck 25(OH)D level after completing the 8-week treatment course
- If levels fail to rise appropriately despite compliance, evaluate for celiac disease or occult cystic fibrosis 1
- For maintenance, periodic monitoring ensures levels remain above 30 ng/mL
Important Caveats
Vitamin D3 (cholecalciferol) is preferred over D2 (ergocalciferol) when available, as research indicates D3 is substantially more potent 3. However, both formulations are acceptable per guidelines 1.
Calcium monitoring: In patients with primary hyperparathyroidism or granulomatous diseases (sarcoidosis, tuberculosis), monitor serum calcium during treatment as these conditions can cause unregulated 1,25(OH)2D production leading to hypercalcemia 1.
The expected rise is approximately 1 ng/mL per 100 IU of daily vitamin D intake 3, meaning the 50,000 IU weekly regimen (equivalent to ~7,000 IU daily) should raise levels by approximately 70 ng/mL over the treatment period, easily achieving the target from a baseline of 13 ng/mL.